• Completed

NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma

Updated: May 21

IFM 99-06

NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma

IFM 99

In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been used since the 1960s and is regarded as the standard of care in elderly patients. We assess whether the addition of thalidomide to this combination or adapted high-dose chemotherapy, using a melphalan 100 mg/m2 -based regimen, would improve survival.


France


Sponsor: University Hospital, Lille


ClinicalTrials.gov Identifier: NCT00367185


Official Title: Comparison of Melphalan-Prednisone(MP),MP-THALIDOMIDE,and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma.

https://clinicaltrials.gov/ct2/show/NCT00367185

 

Thalidomide : National Cancer Institute

Thalidomide : MedlinePlus Drug Information

 

Drug: Thalidomide

Drug: Melphalan

Drug: Prednisone

 

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Lancet; 2007

https://pubmed.ncbi.nlm.nih.gov/17920916/




Posts Archive